

Legends to supplementary figures:

Supplementary Table 1. Cells were seeded at a density of 1×10^4 cells/well in 24-well culture plates and on the following day treated with 1 μ M FZ for 24h. Cells were then trypsinized, viable cells were counted by the trypan blue exclusion method and percentage of surviving cells was calculated. All experiments were done in triplicate.

Supplementary Fig.1. Human H460 or A549 cells were plated onto 96-well tissue culture plates. Cells were left untreated or treated with different doses of FZ or bortezomib for 48 h. Cell viability was determined by MTT assay.

Supplementary Fig.2. Normal immortalized human prostate cells RWPE or mouse primary fibroblasts were seeded onto 96-well tissue culture plates. Cells were left untreated or treated with indicated doses of FZ for 48 h. MTT assay was done to determine cell viability.

Supplementary Fig.3. H460 cell extracts were incubated with FZ and then processed for chymotrypsin like protease activity in a dose or time dependent manner using a specific fluorogenic protease substrate.



Supplementary Fig.4. H460 and A549 cells were plated onto 96 well plates. On the following day, the cells were either left untreated or treated with IKK inhibitor wedelolactone (10 μ M), TNF α (30ng/ml) or FZ (1 μ M) as indicated. Cell viability was measured by MTT assay after 24h.

Supplementary Table 1



Cell line	% survival after FZ treatment*
HOS	56.8
HT29	56.9
MCF-7	44.0
H226	41.7
H460	39.0
A549	45.6
H322	67.1
HeLa	88.5
MDA 453	51.7
SiHa	86.7
HCT116	62.1
SW480	70.2
SK-OV433	59.7
H226Br	79.6
A431	66.7
Du145	69.6
Saos-2	76.4
H1299	82.9
Hep 3B	78.9
HepG2	82.6
H596	86.2
H358	87.5
MDA231	65.0
HT1080	54.4
RD	77.9

* 24h after 1uM FZ treatment



Supplementary Fig.1



Supplementary Fig.2



Supplementary Fig.3



Supplementary Fig.4

